Compare RAYA & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | FGEN |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 35.6M |
| IPO Year | 2022 | 2014 |
| Metric | RAYA | FGEN |
|---|---|---|
| Price | $4.20 | $8.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | 32.8K | ★ 41.3K |
| Earning Date | 04-17-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $27,101,325.00 | $8,298,000.00 |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.16 |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $3.13 | $4.85 |
| 52 Week High | $736.99 | $21.94 |
| Indicator | RAYA | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 44.02 |
| Support Level | $3.95 | $8.30 |
| Resistance Level | $4.50 | $10.47 |
| Average True Range (ATR) | 0.46 | 0.61 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 27.92 | 17.34 |
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.